Evidence-Based Methylxanthine Use in the NICU

Clinics in Perinatology

Volumn 39, Issue 1, 2012, Pages 137-148

  Spitzer, Alan R ^a  

^a PEDIATRIX MEDICAL GROUP   (United States)

Author keywords

Apnea; Caffeine; Methylxanthines; NICU

Indexed keywords

ADENOSINE RECEPTOR; AMINOPHYLLINE; CAFFEINE; CAFFEINE CITRATE; CARBON DIOXIDE; DOXAPRAM; METHYLXANTHINE DERIVATIVE; OXYGEN; THEOPHYLLINE; XANTHINE DERIVATIVE;

BRADYCARDIA; BRONCHODILATATION; CARBON DIOXIDE BREATHING; CARDIOTOXICITY; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; CRYING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ENDOTRACHEAL INTUBATION; EVIDENCE BASED PRACTICE; HEART ARRHYTHMIA; HUMAN; HYPOVENTILATION; IRRITABILITY; LUNG DYSPLASIA; MYOPIA; NECROTIZING ENTEROCOLITIS; NEWBORN APNEA; NEWBORN INTENSIVE CARE; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; RESUSCITATION; RETROLENTAL FIBROPLASIA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TACTILE STIMULATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

APNEA; BRONCHOPULMONARY DYSPLASIA; DUCTUS ARTERIOSUS, PATENT; EVIDENCE-BASED MEDICINE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; INTUBATION, INTRATRACHEAL; XANTHINES;

EID: 84857083522     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2011.12.011     Document Type: Review

References (39)

1. Spitzer A.R., Fox W.W. Infant apnea: an approach to management. Clin Pediatr 1984, 23:374-380.
2. Miller H.C., Behrle F.C., Smull N.W. Severe apnea and irregular respiratory rhythms among premature infants. Pediatrics 1959, 23:676-685.
3. Smith C.A. Diagnosis and treatment: use and misuse of oxygen in treatment of prematures. Pediatrics 1964, 33:111-112.
4. Kerr M. Hyperbaric oxygen in the treatment of apnoea neonatorum. J Obstet Gynaecol Br Commonw 1964, 71:137.
5. Wick H., Schmitt H. Simple warning system for apnoea in premature infants. J Obstet Gynaecol Br Commonw 1967, 71:137.
6. Lewin J.E. An apnoea-alarm mattress. Lancet 1969, 2(7622):667-668.
7. Kuzemko J.A., Paala J. Apnoeic attacks in the newborn treated with aminophylline. Arch Dis Child 1973, 48(5):404-406.
8. Lucey J.E. The xanthine treatment of apnea of prematurity. Pediatrics 1975, 55:584-586.
9. Aranda J.V., Gorman W., Bergsteinsson H., et al. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 1979, 90:467-472.
10. Gunn T.R., Metrakos K., Riley P., et al. Sequelae of caffeine treatment in preterm infants with apnea. J Pediatr 1979, 94:106-109.
11. Bory C., Baltassat P., Porthault M., et al. Metabolism of theophylline to caffeine in premature newborn infants. J Pediatr 1979, 94:988-993.
12. Aranda J.V., Turmen T. Methylxanthines in apnea of prematurity. Clin Perinatol 1979, 6:87-108.
13. Shannon D.C., Gotay F., Stein I.M., et al. Prevention of apnea and bradycardia in low birth weight infants. Pediatrics 1975, 55:589-594.
14. Turmen T., Louridas T.A., Aranda J.V. Relationship of plasma and CSF concentrations of caffeine in neonates with apnea. J Pediatr 1979, 95:644-646.
15. Leon A.E., Michienzi K., Ma C.X., et al. Serum caffeine concentrations in preterm neonates. Am J Perinatol 2007, 24:39-47.
16. Natarajan G., Botica M.L., Thomas R., et al. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?. Pediatrics 2007, 119:936-940.
17. Davis J.M., Stefano J.L., Bhutani V.K., et al. Changes in pulmonary mechanics following caffeine administration in infants with BPD. Pediatr Pulmonol 1989, 6:49-52.
18. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001, 24:31-55.
19. Grosfeld J.L., Dalsing M.C., Hull M., et al. Neonatal apnea, methylxanthines, and necrotizing enterocolitis. J Pediatr Surg 1983, 18:80-84.
20. Davis J.M., Abbasi S., Spitzer A.R., et al. Role of theophylline in pathogenesis of necrotizing enterocolitis. J Pediatr 1986, 109:344-347.
21. Schmidt B., Roberts R.S., Davis P., et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006, 354:2112-2121.
22. Dukhovny D., Lorch S.A., Schmidt B., et al. Economic evaluation of caffeine for apnea of prematurity. Pediatrics 2011, 127:e146-e155.
23. Henderson-Smart D.J., DePaoli A.G. Methyxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev 2010, 12. CD000140.
24. Henderson-Smart D.J., Steer P.A. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev 2010, 1. CD000273.
25. Henderson-Smart D.J., DePaoli A.G. Prophylactic methylxanthine for the prevention of apnoea in preterm infants. Cochrane Database Syst Rev 2010, 12. CD000432.
26. Henderson-Smart D.J., Davis P.G. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010, 12. CD000139.
27. Aranda J.V., Beharry K., Valencia G.B., et al. Caffeine impact upon neonatal morbidities. J Matern Fetal Neonatal Med 2010, 23(Suppl 3):20-23.
28. Pellowski A., Finer N.N. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. J Pediatr 1990, 116:648-653.
29. Barrington K.J., Muttitt S.C. Randomized, controlled, blinded trial of doxapram for extubation of the very low birth weight infant. Acta Paediatr 1998, 87:191-194.
30. Lando A., Klamer A., Jonsbo F., et al. Doxapram and developmental delay at 12 months in children born extremely preterm. Acta Paediatr 2005, 94:1680-1681.
31. Osborn D.A., Henderson-Smart D.J. Kinesthetic stimulation versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev 2001, 4. CD001072.
32. Al-Saif S., Alvaro R., Manfreda J., et al. A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity. J Pediatr 2008, 153:513-518.
33. Pearlman S.A., Duran C., Wood M.A., et al. Caffeine pharmacokinetics in preterm infants older than 2 weeks. Dev Pharmacol Ther 1989, 12:65-69.
34. Ahn H.W., Shin W.G., Park K.J., et al. Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature infants in Korea. Res Commun Mol Pathol Pharmacol 1999, 105:105-113.
35. Charles B.G., Townsend S.R., Steer P.A., et al. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit 2008, 30:709-716.
36. Lorch S.A., Srinivasan L., Escobar G.J. Epidemiology of apnea and bradycardia resolution in premature infants. Pediatr 2011, 128:e366-e373.
37. Eichenwald E.C., Aina A., Stark A.R. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics 1997, 100:354-359.
38. Doyle L.W., Cheong J., Hunt R.W., et al. Caffeine and brain development in very preterm infants. Ann Neurol 2010, 68:734-752.
39. Gray P.H., Flenady V.J., Charles B.G., et al. Caffeine citrate for very preterm infants: effects on development, temperament, and behavior. J Paediatr Child Health 2011, 47:167-172.